ClinicalTrials.gg
CompletedNCT05610813ELEVATEUpdated Nov 25, 2024

Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain

A Phase 3 interventional study of VER-01 and Opioid therapy in Chronic Non-specific Low Back Pain, sponsored by Vertanical GmbH. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Vertanical GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Enrollment
11th of 54
384 · median 128
Started
2023
with 7 others
Phase 3
14 of 59
2 open now
Registered
49th of 59
by date
Lead sponsor
2 of 59
Vertanical GmbH

Among the 59 studies in Low Back Pain with a site in Germany, this one is the 11th largest by enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2023, is one of 14 in phase 3, and was the 49th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Read the detailed description

The test intervention VER-01 is a cannabis-based pain medication currently under clinical development that is expected to provide adequate pain relief while being better tolerated in long-term treatment compared to opioid analgesics. This study aims to demonstrate the superior tolerability, especially in terms of bowel function, of VER-01 compared to existing authorised and marketed opioid analgesics in patients with chronic non-specific low back pain. In addition, the safety and tolerability as well as the efficacy of VER-01 compared to opioid therapy will be evaluated.

03

Conditions studied

  • Chronic Non-specific Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients ≥18 years of age
  2. Provision of form voluntarily signed and dated by the patient
  3. For women of and men of : use of a reliable method (Pearl index \< 1) at least 1 month before the start of the study and willingness to use it during the study participation and 3 months after the last intake of the test or comparative intervention
  4. Patient understands the local language and is willing and able to comply with scheduled visits, treatment plan, patient diary and other study related procedures throughout study participation
  5. Chronic (for at least 3 months) non-specific pain in the lower back (between the 12th thoracic vertebra and lower gluteal folds). Non-specific pain refers to pain without a clear specific treatable cause.
  6. Patients with indicated drug treatment where previous optimized treatments with non-opioid analgesics (including combinations) have not led to sufficient pain relief or were unsuitable due to or intolerance.
  7. Low back pain intensity on average at least 4 points on an 11-point Numeric Rating Scale in the last 4 weeks prior visit 1
  8. Ongoing non-drug pain therapy (physical or behavioral therapy) must have been stable for at least 2 weeks prior visit 1 and must be continued during the run-in phase
  9. Ongoing additional analgesic treatment prior visit 1 must be continued during the run-in phase
  10. Bowel Function Index total score of 28.8 or less at visit 1.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a known history of alcohol/drug/medication abuse or dependency and previous or current use of methadone
  2. Evidence of drugs of abuse or illegal drugs by urine drug test performed at visit 1
  3. Known intolerance or to ingredients of rescue medication, opioid therapy (assigned by the investigator) and/or VER-01
  4. Participation in another clinical interventional study within the last 30 days prior screening visit (visit 1)
  5. Occupational groups with primary activity of operating machinery and driving motor vehicles
  6. Planned blood donation or planned donation or freezing of sperm or oocytes during study participation and 3 months after end of study participation
  7. Pregnant or breastfeeding female patients
  8. Patient is unable to provide written , in need for care, has a guardian/caretaker, is immobile, or is particularly vulnerable (e.g., imprisoned; institutionalised by a court or judicial authority; dependent or employed by the sponsor, an external service provider of the sponsor (involved in the conduct of the study), the investigator or the trial site)
  9. Known use of opioid or cannabis-based treatments within 30 days before screening visit (visit 1)
  10. Patients for whom cannabis or opioid therapy is not indicated, e.g., due to a history of non-response to opioid therapy or cannabis-based medicines in the treatment of chronic non-specific low back pain in the past.
  11. Start of or planned non-drug pain therapy during run-in phase (physical or behavioral therapy)
  12. Start or planned start of an additional analgesic treatment during run-in phase
  13. Ongoing monoamine oxidase inhibitor therapy at screening visit (visit 1)
  14. Patients with history of cancer in the last 5 years prior to screening visit (visit 1). Except for cutaneous basal cell or squamous cell cancer resolved by excision without recurrence and cervical cancer in situ resolved by excision with negative pap test.
  15. Painful comorbidities which could interfere with the low back pain intensity assessment during the study
  16. Known history of (HIV) infection
  17. Severe forms of the following diseases: Anaemia, haematological / / endocrine / renal / hepatic / respiratory / cardiovascular / neurological / gastrointestinal / symptomatic peripheral vascular diseases.
  18. Cardiovascular event in the last three months before screening visit (visit 1)
  19. Known uncontrolled hypertension (average systolic blood pressure ≥140 mmHg or average diastolic blood pressure

    ≥90 mmHg) and/or untreated hypothyroidism

  20. Patients with Crigler-Najjar syndrome, Rotor syndrome and/or porphyria
  21. History of major trauma or back surgery in the last 2 months prior to screening visit (visit 1)
  22. Known history of or current severe psychiatric illness
  23. Known history of or current severe depression (not due to chronic low back pain) (assessed by Patient Health Questionnaire - 9) and/or suicidal ideation (assessed by Columbia-Suicide Severity Rating Scale) at screening visit (visit 1)
  24. Patients with severe respiratory depression
  25. Patients with lung disease associated with impaired lung function (e.g., acute or severe bronchial asthma or hypercapnia/respiratory failure).
  26. Patients with conditions of increased intracranial pressure due to head injury or disease of the brain.
  27. Patients with existing or suspected paralytic ileus
  28. Patients with intestinal obstruction due to intestinal paralysis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    Test intervention: VER-01

    VER-01 will be administered twice daily to patients randomized to treatment arm VER-01.

    Drug: VER-01

  • Active comparator
    Comparative intervention: Opioid therapy (with an authorised and marketed opioid, ATC code N02A)

    Opioids will be administered according to the SmPC to patients randomized to treatment arm opioid therapy.

    Drug: Opioid therapy

Interventions

  • DrugVER-01

    Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product

    Also known as: trans-Δ9-Tetra-hydrocannabinol (THC)

  • The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.

    Also known as: Opioids

06

What researchers measure

Primary outcomes

  1. Risk of developing constipation

    Number and proportion of constipation responders at the end of treatment phase (Visit 9). A constipation responder is defined as a patient with 1. a change from baseline (visit 2) in Bowel Function Index (BFI) total score of at least 15 points at Visit 9 and 2. a BFI total score of more than 28.8 at Visit 9.

    Time frame: 190 days

Secondary outcomes

  1. Efficacy based on pain reduction

    Number and percentage of 30% pain responders at study week 27 (last week of treatment phase) compared with the baseline score (study week -1)

    Time frame: 190 days

  2. Efficacy based on pain reduction in NE patients

    Number and percentage of 30% pain responders in the subgroup of patients with a neuropathic pain component (painDETECT score \>18) at study week 27 compared with the baseline score (study week -1)

    Time frame: 190 days

  3. Efficacy based on pain reduction and interference with sleep

    Number and percentage of patients with a 30% improvement of the mean daily low back pain interference with sleep score evaluated on an 11-point Numeric Rating Scale (NRS) at study week 27 compared with the baseline score (study week -1)

    Time frame: 190 days

07

Study locations

2 sites
  • Rheumazentrum Prof. Dr. med. Gunther Neeck
    Bad Doberan, 18209, Germany
  • Medizinische Hochschule Hannover (MHH)
    Hannover, 30625, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2024, 16 months.

Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 9, 2022
StartActual
Jun 8, 2023
Primary completionActual
Oct 18, 2024
CompletionActual
Oct 18, 2024
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610813
Lead sponsor
Vertanical GmbH
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Jun 8, 2023
Primary completion
Oct 18, 2024
Completion
Oct 18, 2024
Last update
Nov 25, 2024

Study contacts

Matthias Karst, Prof.Dr.med.
principal investigator · Medizinische Hochschule Hannover (MHH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VER-01

Start the discussion